secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalyn Pharma Inc. (AVLN)
CIK:        0001540171
Form:       8-K
Filed at:   2026-08-12T12:06:35+00:00
Accession:  0001193125-26-345807
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalyn reports Q2 net loss $28.9M; completes MIST enrollment with 398 patients
------------------------------------------------------------------------------

- Net loss $28.9M in Q2 2026 vs $20.2M in Q2 2025; R&D $24.7M, G&A $6.6M.
- Cash, equivalents, marketable securities $413.5M at June 30, 2026; runway into 2029.
- MIST Phase 2b fully enrolled with 398 patients (target 375); topline data expected H2 2027.
- AURA Phase 2 enrollment on track (160 patients); topline late 2027; AP03 Phase 1 to start by end 2026.
- May 2026 IPO raised ~$316.6M in net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/0001193125-26-345807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer